{"prompt": "['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Revised text:', 'Text deleted.', '12.5 Appendix 5: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Original text:', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', \"Investigator will attempt to collect pregnancy information on any male participant's\", 'female partner of a male study participant who becomes pregnant while participating', 'in this study. This applies only to participants who receive study treatment.', 'After obtaining the necessary signed informed consent from the pregnant female', 'partner directly, the investigator will record pregnancy information on the', \"appropriate form and submit it to GSK within 24 hours of learning of the partner's\", 'pregnancy.', 'Partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', 'Generally, follow-up will be no longer than 6 to 8 weeks following the estimated', 'delivery date. Any termination of the pregnancy will be reported regardless of fetal', 'status (presence or absence of anomalies) or indication for procedure.', 'Revised text:', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', 'Investigator will not routinely attempt to collect pregnancy information on any', \"male participant's female partner(s) who becomes pregnant while the male\", 'participant is participating in this study; however, voluntary reports of such', 'incidents will be captured through the GSK standard reporting mechanism. This', 'applies only to male participants who receive double-blind study treatment.', \"If pregnancy information for a male participant's female partner(s) is voluntarily\", 'reported, after obtaining the necessary signed informed consent from the pregnant', 'female partner directly, the investigator will record pregnancy information on the', \"appropriate form and submit it to GSK within 24 hours of learning of the partner's\", 'pregnancy.', 'Partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', '104']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Generally, follow-up will be no longer than 6 to 8 weeks following the', 'estimateddelivery date. Any termination of the pregnancy will be reported', 'regardless of fetal status (presence or absence of anomalies) or indication for', 'procedure', '105']['2016N293064 0', 'CONFIDENTIAL', '2018N394263_00', 'GlaxoSmithKline group of companies', '205864', 'TITLE PAGE', 'Protocol Title: A randomized, double-blind, Sponsor open, placebo-controlled, 52 week', 'study evaluation the effect of danirixin (GSK1325756) on lung function and health', 'related quality of life in participants with mild to moderate Chronic Obstructive', 'Pulmonary Disease (COPD).', 'Protocol Number: 205864 Amendment 1', 'Short Title: Danirixin Pilot Study for Disease Progression', 'Compound Number: GSK1325756', 'Sponsor Name and Legal Registered Address:', 'GlaxoSmithKline Research & Development Limited', '980 Great West Road', 'Brentford', 'Middlesex, TW8 9GS', 'UK', 'Medical Monitor Name and Contact Information will be provided in the Study', 'Reference Manual', 'Regulatory Agency Identifying Number(s): IND: 108168', 'Approval Date: 17-MAY-2017', 'Copyright 2017 the GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorised copying or use of this information is prohibited.', '1']\n\n###\n\n", "completion": "END"}